(Total Views: 564)
Posted On: 02/09/2021 9:08:09 AM
Post# of 155750
The mortality numbers today in the NeuroRX / RLFTF PR seems encouraging
Quote:
"A total of 203 patients were screened and consented to participate in the study; 136 were given ZYESAMI. while 67 received the standard of care. All patients were evaluated through Day 28 with planned long-term follow-up through day 60. A total of 138 patients (91 ZYESAMI, 47 SOC) survived through Day 28. Ninety-six patients (65 ZYESAMI, 31 SOC) were discharged from the hospital by Day 28. Data analysis per protocol is ongoing."
Disclaimer: I'm no statistician
That comes out to mortality rates of 33% in AVIP and 30% SOC
30% x 131 SOC patients in LL study = 39 deaths
Assuming about 90 deaths total in the LL study
51 LL deaths / 262 LL patients = 19-20% mortality
this looks like a 33+ % reduction in mortality.
I also believe the LL study allowed for sicker patients to enroll? Which I would think likely increases the SOC mortatlity rate.
Would love some input.
Quote:
"A total of 203 patients were screened and consented to participate in the study; 136 were given ZYESAMI. while 67 received the standard of care. All patients were evaluated through Day 28 with planned long-term follow-up through day 60. A total of 138 patients (91 ZYESAMI, 47 SOC) survived through Day 28. Ninety-six patients (65 ZYESAMI, 31 SOC) were discharged from the hospital by Day 28. Data analysis per protocol is ongoing."
Disclaimer: I'm no statistician
That comes out to mortality rates of 33% in AVIP and 30% SOC
30% x 131 SOC patients in LL study = 39 deaths
Assuming about 90 deaths total in the LL study
51 LL deaths / 262 LL patients = 19-20% mortality
this looks like a 33+ % reduction in mortality.
I also believe the LL study allowed for sicker patients to enroll? Which I would think likely increases the SOC mortatlity rate.
Would love some input.
(5)
(0)
